ResMed appoints Shubhi Khurana as New India, South Asia General Manager; to help increase awareness about sleep apnea
Shubhi Khurana has more than two decades of experience in the pharmaceutical, healthcare, and medtech industries in various leadership roles.
NEW DELHI: ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.
Ms Khurana, former general manager of Capsugel India Region (now Lonza), oversees business operations including setting strategic priorities, evolving team and go-to-market models for ResMed’s long-term growth. She aims to enhance ResMed’s leadership in the region by enabling efforts in developing innovative technology-enabled care pathways and improving patients’ therapy experiences.
These initiatives also encompass market development and awareness measures to educate the public, medical community, and decision makers about the prevalence of sleep and respiratory diseases in South Asia, as well as how to diagnose and treat them at home with cloud-connectable non-invasive devices. These campaigns support efforts to address the under-penetration of sleep and respiratory care markets in India and neighbouring countries and help millions of people improve their quality of life.
An estimated 52 million Indians have sleep apnea – the vast majority are undiagnosed – and 55 million have COPD (chronic obstructive pulmonary disease), the fourth leading cause of death annually worldwide, according to the World Health Organization.
Commenting on the approval, Justin Leong, president of ResMed’s Asia Growth Markets said, “Sleep apnea and COPD are global health epidemics and are especially prevalent in Asia.”
“In India, these diseases are highly underdiagnosed due to low awareness amongst both doctors and the general community. Given the link between these diseases, and other chronic diseases like diabetes, hypertension, stroke, cognitive disorders and cancer, it is critical we continue to educate and treat people with these conditions. We are thrilled to have Shubhi join us at this important time,” Justin added.
On being appointed as the General Manager, Khurana said, “I am excited to accept this critical role and to grow both public awareness of the health epidemics ResMed helps treat and ResMed’s own reputation as an important digital health leader in this space."
"Research on the impacts of sleep apnea and COPD are only a few decades old. Therefore, the potential to make an impact in people lives and their health through ResMed’s innovative offerings is a great opportunity in itself, ” she added.
Khurana has more than two decades of experience in the pharmaceutical, healthcare, and medtech industries in various leadership roles. Before Capsugel, she worked at Baxter and Baxalta (now Takeda), building their Critical Care, Rare Diseases, and Surgical Kits business.
Also Read: ResMed seeks patent injunction on Fisher and Paykel Healthcare
NEW DELHI: ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.
Ms Khurana, former general manager of Capsugel India Region (now Lonza), oversees business operations including setting strategic priorities, evolving team and go-to-market models for ResMed’s long-term growth. She aims to enhance ResMed’s leadership in the region by enabling efforts in developing innovative technology-enabled care pathways and improving patients’ therapy experiences.
These initiatives also encompass market development and awareness measures to educate the public, medical community, and decision makers about the prevalence of sleep and respiratory diseases in South Asia, as well as how to diagnose and treat them at home with cloud-connectable non-invasive devices. These campaigns support efforts to address the under-penetration of sleep and respiratory care markets in India and neighbouring countries and help millions of people improve their quality of life.
An estimated 52 million Indians have sleep apnea – the vast majority are undiagnosed – and 55 million have COPD (chronic obstructive pulmonary disease), the fourth leading cause of death annually worldwide, according to the World Health Organization.
Commenting on the approval, Justin Leong, president of ResMed’s Asia Growth Markets said, “Sleep apnea and COPD are global health epidemics and are especially prevalent in Asia.”
“In India, these diseases are highly underdiagnosed due to low awareness amongst both doctors and the general community. Given the link between these diseases, and other chronic diseases like diabetes, hypertension, stroke, cognitive disorders and cancer, it is critical we continue to educate and treat people with these conditions. We are thrilled to have Shubhi join us at this important time,” Justin added.
On being appointed as the General Manager, Khurana said, “I am excited to accept this critical role and to grow both public awareness of the health epidemics ResMed helps treat and ResMed’s own reputation as an important digital health leader in this space."
"Research on the impacts of sleep apnea and COPD are only a few decades old. Therefore, the potential to make an impact in people lives and their health through ResMed’s innovative offerings is a great opportunity in itself, ” she added.
Khurana has more than two decades of experience in the pharmaceutical, healthcare, and medtech industries in various leadership roles. Before Capsugel, she worked at Baxter and Baxalta (now Takeda), building their Critical Care, Rare Diseases, and Surgical Kits business.
Also Read: ResMed seeks patent injunction on Fisher and Paykel Healthcare
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd